Dr. AAZAMBIR BRAR
Dr. ARVIND TENAGI, Dr. Vivek Wani
Abstract
Methods: Eyes with DME with CMT>260 microns and BCVA of 6/9 (0.18 logMAR units) or worse were recruited and given three monthly IVB. BCVA and CMT at the end of four months were assessed and compared to baseline values. Side effects were noted if any.
Results: The mean BCVA at baseline and at 4 months were 0.80 ± 0.49 and 0.51 ± 0.36 respectively (p value =0.0001). The mean baseline CMT (μm) and at 4 months were 448.40 ± 149.47 and 368.76 ± 131.49 (p value =0.0001) respectively. The improvement in BCVA and CMT were statistically significant. Various factors like duration of diabetes and value of HbA1c were not found to be significant for the improvement in BCVA and CMT.
Conclusion: IVI bevacizumab given as 3 monthly injections was safe and effective in DME management.
Leave a Comment